Nadine Tung

机构：Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber Cancer Institute · ORCID：0000-0003-1422-3734

发表论文 485 篇 · 总被引 31318 次 · h-index 85

代表论文

• Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. (2025 · Journal of Clinical Oncology · 被引 24)
• HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis (2025 · The Lancet Oncology · 被引 20)
• A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. (2025 · Journal of Clinical Oncology · 被引 12)
• Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study (2025 · Breast Cancer Research · 被引 5)
• Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant (2025 · British Journal of Cancer · 被引 2)
• Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer (2025 · medRxiv · 被引 1)